GO
Loading...

Eli Lilly and Co

More

  • Lilly receives European marketing OK for insulin Wednesday, 10 Sep 2014 | 10:13 AM ET

    INDIANAPOLIS— European regulators have approved a long-lasting insulin from Eli Lilly and Co. and German drugmaker Boehringer Ingelheim that is the subject of patent infringement litigation with French rival Sanofi. That is subject to a stay of more than two years due to the Sanofi litigation.

  • Sept 10- Eli Lilly and Co and Boehringer Ingelheim said on Wednesday that the European Commission approved their copycat version of Sanofi SA's blockbuster insulin, Lantus. The therapy received a positive recommendation from the European Medicine Agency in June.

  • Final Glance: Pharmaceuticals companies Tuesday, 9 Sep 2014 | 8:15 PM ET

    Baxter International Inc. rose$. 05 or. 1 percent, to $74.27. Bristol-Myers Squibb Co. fell$. 71 or 1.4 percent, to $50.48. Hospira rose$. 29 or. 6 percent, to $53.01.

  • Midday Glance: Pharmaceuticals companies Tuesday, 9 Sep 2014 | 1:22 PM ET

    Baxter International Inc. rose$. 12 or. 2 percent, to $74.34. Bristol-Myers Squibb Co. fell$. 46 or. 9 percent, to $50.73. Hospira rose$. 29 or. 6 percent, to $53.01.

  • Early Glance: Pharmaceuticals companies Tuesday, 9 Sep 2014 | 10:26 AM ET

    Baxter International Inc. rose$. 04 or. 1 percent, to $74.26. Bristol-Myers Squibb Co. fell$. 47 or. 9 percent, to $50.72. Hospira rose$. 01 or percent, to $52.73.

  • Final Glance: Pharmaceuticals companies Monday, 8 Sep 2014 | 6:38 PM ET

    Baxter International Inc. rose$. 02 or percent, to $74.22. Bristol-Myers Squibb Co. rose$. 07 or. 1 percent, to $51.19. Hospira fell $1.18 or 2.2 percent, to $52.72.

  • Midday Glance: Pharmaceuticals companies Monday, 8 Sep 2014 | 1:36 PM ET

    Baxter International Inc. rose$. 40 or. 5 percent, to $74.60. Bristol-Myers Squibb Co. fell$. 01 or percent, to $51.11. Hospira fell$. 88 or 1.6 percent, to $53.02.

  • Early Glance: Pharmaceuticals companies Monday, 8 Sep 2014 | 10:34 AM ET

    Baxter International Inc. rose$. 06 or. 1 percent, to $74.26. Bristol-Myers Squibb Co. rose$. 02 or percent, to $51.14. Hospira fell $1.22 or 2.3 percent, to $52.68.

  • Midday Glance: Pharmaceuticals companies Friday, 5 Sep 2014 | 3:45 PM ET

    Baxter International Inc. rose$. 67 or. 9 percent, to $74.38. Bristol-Myers Squibb Co. rose$. 32 or. 6 percent, to $50.87. Hospira rose$. 42 or. 8 percent, to $53.85.

  • Early Glance: Pharmaceuticals companies Friday, 5 Sep 2014 | 10:12 AM ET

    Baxter International Inc. rose$. 39 or. 5 percent, to $74.10. Bristol-Myers Squibb Co. rose$. 08 or. 2 percent, to $50.63. Hospira rose$. 39 or. 7 percent, to $53.82.

  • Final Glance: Pharmaceuticals companies Thursday, 4 Sep 2014 | 5:57 PM ET

    Baxter International Inc. fell$. 26 or. 4 percent, to $73.71. Bristol-Myers Squibb Co. rose$. 02 or percent, to $50.55. Hospira fell$. 42 or. 8 percent, to $53.43.

  • Midday Glance: Pharmaceuticals companies Thursday, 4 Sep 2014 | 1:16 PM ET

    Baxter International Inc. rose$. 21 or. 3 percent, to $74.18. Bristol-Myers Squibb Co. fell$. 01 or percent, to $50.52. Hospira fell$. 02 or percent, to $53.83.

  • Lilly says insulin fares well in late-stage tests Thursday, 4 Sep 2014 | 11:03 AM ET

    INDIANAPOLIS— Eli Lilly and Co. plans to seek approval early next year for a new insulin it developed after the diabetes treatment fared better than the competition in two late-stage clinical studies.

  • Early Glance: Pharmaceuticals companies Thursday, 4 Sep 2014 | 10:27 AM ET

    Baxter International Inc. rose$. 54 or. 7 percent, to $74.51. Bristol-Myers Squibb Co. rose$. 03 or. 1 percent, to $50.56. Hospira rose$. 26 or. 5 percent, to $54.11.

  • Smaller cloud companies chase new business models Monday, 25 Aug 2014 | 12:00 AM ET

    Nothing concentrates minds at a tech start-up like living in the middle of a price war between Amazon and Google. NYT reports.

  • Aug 21- An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG.

  • Aug 21- Eli Lilly and Co said its experimental psoriasis drug was found to be more effective in clearing skin than a generic treatment and a placebo in late-stage studies. The most common inflammatory disease in the United States- it can occur on any part of the body- it is associated with diabetes and heart disease.

  • Lilly psoriasis drug succeeds in late-stage studies Thursday, 21 Aug 2014 | 7:16 AM ET

    Aug 21- Eli Lilly and Co said its experimental psoriasis drug was found to be more effective in clearing skin than a generic treatment and a placebo in late-stage studies. Three studies evaluated the drug, ixekizumab, against the generic etanercept and a placebo, in patients with moderate-to-severe plaque psoriasis.

  • Early movers: HD, BHP, BAC, URBN, RDEN, LLY & more Tuesday, 19 Aug 2014 | 7:56 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • SAN FRANCISCO, Aug 14- A group of ex-gaming industry executives say they can use their design chops to solve a major health challenge: Sick patients neglecting to take their medication and costing employers and insurance providers billions of dollars.